Supernus earnings missed by $0.21, revenue topped estimates
Supernus (SUPN) reported Q3 EPS of $0.35, missing estimates by $0.21, but revenue of $226.8M exceeded expectations. The stock is down 6.25% over 3 months and 25.95% over 12 months. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
Traders will likely focus on whether the EPS miss reflects controllable items versus a broader earnings power issue, using the revenue beat as a partial offset.
Market read
A clear EPS miss versus estimates is the key datapoint, with revenue beating consensus and the stock closing down on the day.
What to watch
The piece does not include guidance, margins, or management commentary, which are typically what determine whether the EPS miss is a one-off versus a trend.
Background
The article reports Supernus’s Q3 results versus consensus and notes recent EPS revision activity.
Ticker impact
Supernus reported Q3 EPS of $0.35, missing the $0.56 estimate, while revenue of $226.8M topped $218.54M consensus.
Likely downward pressure as the market reprices the EPS shortfall and weighs whether revenue strength offsets margin or cost concerns.
The article’s only company-specific negative surprise is the EPS miss versus consensus; it also notes the stock closed lower and has been weak over 3 and 12 months.
Market effects
Limited spillover; this is a single-company earnings print with no sector-wide guidance or regulatory catalyst mentioned.
No specific regional macro linkage beyond general US small/mid-cap sentiment.
None indicated; the article contains no international demand, supply, or policy drivers.
Counterpoint
Revenue beat could indicate demand resilience, so the EPS miss may be temporary (timing, one-offs, or cost normalization) rather than a structural deterioration.
Key entities
- companySupernus
NASDAQ-listed biopharma company reporting Q3 EPS and revenue versus analyst consensus.
